Jump Financial’s Carisma Therapeutics CARM Stock Holding History

Jump Financial’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-17,542	Closed	-$54.4K	–	1822
2023 Q1	$54.4K	Buy	+17,542	New	+$167K	﹤0.01%	1494

Other funds holding CARM

TOTUOP

Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jump Financial's CARM Position: Q2 2023 in Review

Jump Financial sold out of Carisma Therapeutics (CARM) in Q2 2023, closing a stake of 17,542 shares — an estimated $54.4K sold.

Jump Financial first reported a position in CARM in Q1 2023 and held it in 1 quarter. The position peaked at $54.4K in Q1 2023. 53 funds tracked by Wall St. Rank hold CARM as of Q2 2023.

Jump Financial reported no remaining Carisma Therapeutics position as of Q2 2023 after selling out during the quarter.
Jump Financial sold 17,542 Carisma Therapeutics shares in Q2 2023, an estimated $54.4K.
Jump Financial first reported a position in Carisma Therapeutics in Q1 2023 and held it in 1 quarter.
Jump Financial's Carisma Therapeutics position peaked at $54.4K in Q1 2023.
53 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2023.

Based on Jump Financial's 13F filing for Q2 2023, filed 7 Aug 2023.